Biologics & Biosimilars

Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis

August 7, 2020 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis

July 15, 2020

Biosimilar Prescribing Habits in the VA & Academic Settings

June 29, 2020 • By Arthritis & Rheumatology

Medicalwriters/Science Source

Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

June 15, 2020 • By Bryn Nelson, PhD

U.S. Insurers Often Limit Biosimilar Coverage

May 29, 2020 • By Lisa Rapaport

Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions

May 18, 2020 • By Catherine Kolonko

Sentavio / shutterstock.com

Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same

May 15, 2020 • By Kimberly Retzlaff

Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

March 12, 2020 • By Thomas R. Collins

Clinicians Discuss Current & Future Rheumatoid Arthritis Approaches

March 12, 2020 • By Mike Fillon

FDA Update: New Drug Approvals, New & Expanded Indications, & More

March 12, 2020 • By Susan Bernstein